Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M6GC
|
||||
| Former ID |
DIB007271
|
||||
| Drug Name |
TRU-015
|
||||
| Synonyms |
CytoxB20G; XXX_CytoxB20G; CD20 antagonist, Trubion; PF-5212374
|
||||
| Indication | Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] | Phase 2 | [1] | ||
| Company |
Trubion Pharmaceuticals Inc; Trubion
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00634933) Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
| REF 2 | TRU-015, a small modular immunopharmaceutical (SMIP?? drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.